Quotient Therapeutics

Our #SomaticGenomics platform follows a novel approach to uncovering links between genes and disease. This reveals a path to develop transformative therapeutics with intrinsically validated targets. Discover how our platform works: bit.ly/3AkWg71

As part of our commitment to give back to the community, we volunteered with @FlagshipPioneer & fellow #FlagshipFounded companies to support several orgs including #ThompsonIslandOutwardBound, #ScienceClubforGirls, @TheFoodProject, #CoFarmUK, #SecondChanceCars, & STEAM Ahead.

#SomaticMutations are genetic changes in our cells that can cause disease or protect cells from it. Our platform uncovers these changes, enabling the development of novel therapies to imitate or inhibit the mutation’s impact. Learn more: bit.ly/3HUju7J

On the latest episode of the @NucleateHQ Podcast, our CSO, Peter Campbell, shares his career journey from pioneering early cancer genome sequencing efforts at the Sanger Institute to now leading the advancement of our #SomaticGenomics platform. Listen here:bit.ly/3HHEFty

We were honored to welcome Congressman Jake Auchincloss (MA-04) for a tour of our labs and showcase the advancements we’re making with our #SomaticGenomics platform!

Our #SomaticGenomics platform goes beyond traditional genetic approaches to uncover the direct link between genes and diseases. Learn about our platform's capabilities: bit.ly/3AkWg71

We're continually inspired by the talent and dedication of our team at Quotient. As our Director of Structural Biology, Ao Yang, exemplifies this through a deep passion for studying #SomaticMutations at the molecular level to identify new drug targets. #QuotientVisionary

Welcome, Rahul Kakkar, as our new CEO at Quotient and CEO-Partner at @FlagshipPioneer. His wealth of experience as a biotech entrepreneur and physician-scientist will be invaluable as we propel our #SomaticGenomics platform forward. Read here: quotient-tx.com/news/flagship-…

On National DNA Day, we celebrate the remarkable strides in genetic research made by scientists before us. Their work paved the way for our #SomaticGenomics platform, which uncovers novel links between genes and disease to advance transformative therapeutics. #DNADay25

At Quotient, we’re proud to have such a talented team! Qin Wang brings her passion for collaboration to the team in her work as an Applied Statistical Geneticist focused on using #SomaticGenomic insights to identify priority drug targets for development. #QuotientVisionary

Our #SomaticGenomic platform not only identifies links between genes & disease but can also help us develop diverse therapeutic modalities—from small molecules to gene therapies & beyond. Learn how we’re uncovering new treatment possibilities: bit.ly/3UzKYTP

To celebrate #InternationalWomensDay, we're highlighting the incredible women on our team, like Kelly Becker, whose work as an Associate Scientist of Assay Development helps to advance our #SomaticGenomics platform. Learn about our values bit.ly/3WLvOei #WomenInSTEM

#ICYMI, our CEO, Jacob Rubens, spoke on one of @FlagshipPioneer’s panels at #JPM25 about the power of platform technologies. Tune in as he discusses the development of our #SomaticGenomics platform & its potential impact on #DrugDiscovery and development: bit.ly/3WvxQjA

This International Day of #WomenAndGirlsInScience, we're celebrating the incredible women on our team whose passion and expertise drive innovation and inspire us daily as we pioneer the field of #SomaticGenomics. #WomenInSTEM

In this @MedNous article, our CEO, Jake Rubens, shares how advancements in #SomaticGenomic analysis are redefining our understanding of biology and driving the development of innovative therapies. Read more here: bit.ly/4hH793x

From the double helix to the Human Genome Project, UK & US teams have long shaped biology’s future. With UK #SomaticGenomics research & US biotech expertise, we're using genetics to transform medicine. Read more from @GeorgiaBanjo in @TheEconomist: bit.ly/4aIeKfU

#ICYMI our Head of Platform, Simon Brunner, was featured in the latest @PharmaScrip Asks issue discussing the role that AI and #SomaticGenomics play to uncover novel drug targets informed by the true complexity of human biology. Read more here: bit.ly/3PWQjBR

From pipeline developments and clinical milestones to new partnerships, hear from the CEOs and leaders of #FlagshipFounded companies advancing novel science and platforms to make #BiggerLeaps for human health. Watch all the conversations: flagshippioneering.com/topics/ceo-cha… 🔹 Lovisa…

Our CEO, Jacob Rubens, visited the @FlagshipPioneer Studio at this year's J.P. Morgan conference to discuss how Quotient is using #SomaticGenomics to transform drug discovery and development, as well as highlight some recent progress from the company. #FlagshipJPM #JPM25

Polyintelligence: the fusion of human, machine & nature's intelligence. In @FlagshipPioneer's annual letter, Founder & CEO Noubar Afeyan explores polyintelligence. See how we're pioneering a new frontier of human genetics in a case study featured here: flagshippioneering.com/polyintelligen…